Yanni Souroutzidis
Stock Analyst at Cantor Fitzgerald
(0.22)
# 4,585
Out of 5,005 analysts
7
Total ratings
n/a
Success rate
-39.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Yanni Souroutzidis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGMT Sagimet Biosciences | Initiated Coverage: Buy | $26 | $9.94 | +161.57% | 1 | Sep 9, 2026 | |
| KPTI Karyopharm Therapeutics | Reiterated: Buy | $3.68 | $1.62 | +127.16% | 3 | Sep 1, 2026 | |
| AGMB AgomAb Therapeutics NV | Initiated Coverage: Buy | $17 | $10.21 | +66.50% | 1 | Aug 19, 2026 | |
| TRDA Entrada Therapeutics | Initiated Coverage: Buy | n/a | $6.22 | - | 1 | Apr 1, 2026 | |
| TSX: MSCL Satellos Bioscience Inc. | Initiated Coverage: Buy | n/a | $12.62 | - | 1 | Mar 11, 2026 |
Sagimet Biosciences
Sep 9, 2026
Initiated Coverage: Buy
Price Target: $26
Current: $9.94
Upside: +161.57%
Karyopharm Therapeutics
Sep 1, 2026
Reiterated: Buy
Price Target: $3.68
Current: $1.62
Upside: +127.16%
AgomAb Therapeutics NV
Aug 19, 2026
Initiated Coverage: Buy
Price Target: $17
Current: $10.21
Upside: +66.50%
Entrada Therapeutics
Apr 1, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $6.22
Upside: -
Satellos Bioscience Inc.
Mar 11, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $12.62
Upside: -